Repositioning Candidate Details
| Candidate ID: | R0999 |
| Source ID: | DB06395 |
| Source Type: | investigational |
| Compound Type: | small molecule |
| Compound Name: | Abafungin |
| Synonyms: | Abafungin |
| Molecular Formula: | C21H22N4OS |
| SMILES: | CC1=CC(C)=C(OC2=CC=CC=C2C2=CSC(N=C3NCCCN3)=N2)C=C1 |
| Structure: |
|
| DrugBank Description: | -- |
| CAS Number: | 129639-79-8 |
| Molecular Weight: | 378.49 |
| DrugBank Indication: | Investigated for use/treatment in fungal infections, bacterial infection, skin infections/disorders, and onychomycosis. |
| DrugBank Pharmacology: | -- |
| DrugBank MoA: | Abafungin has been shown to have fungicidal and fungistatic effects on a wide variety of pathogens, including dermatophytes, yeasts (Candida) and moulds. The drug acts on the infecting organisms in two ways: by interfering with the formation of a vital sterol in the fungal cell membrane, thereby preventing cell growth, and also by direct interaction with another membrane component resulting in membrane disruption, leakage of cellular contents and death of the cell and independent of whether it is in a non-metabolising (`resting') phase of development or actively growing. These features of abafungin, combined with the attainment of microbicidal concentrations in the skin from a 1% preparation, its long residence at the site of dermal application and the lack of significant systemic absorption, mean that Abasol(tm) is particularly attractive for the topical treatment of dermatomycoses, which is the first indication under review for marketing approval. |
| Targets: | -- |
| Inclusion Criteria: | Indication associated |
